Oppenheimer still likes Abbott, just less wildly

Still a thumbs-up, just with a smaller grin

Oppenheimer’s Suraj Kalia left Abbott Laboratories with an Outperform rating on April 17, but nudged the price target down from $132 to $115. Translation: the analyst still thinks the stock can work, just not quite as spectacularly as before.

The market’s version of “I like you, but…”

This is one of those classic Wall Street moves where the relationship status stays the same, but the enthusiasm gets a little less caffeinated. A lower target usually means the analyst sees more near-term headwinds, softer sentiment, or a valuation that already did some of the heavy lifting.

For Abbott, that comes after a broader wave of analyst trimming. In other words, Oppenheimer isn’t exactly an outlier here — it’s more like another person in the room saying, “Yeah, maybe set the expectations a bit lower.”

Why investors should care

Abbott is still getting credit for strong fundamentals, and the company’s business isn’t exactly falling apart. But analysts are clearly rethinking how much juice is left in the stock near term.

• The new target still sits above the current share price.
• The rating remains positive, so this is not a “run for the hills” moment.
• But the cut signals less room for error if growth slows or margins wobble.

Big picture

For you as an investor, this is less about a dramatic downgrade and more about expectations management. Abbott is still in the good graces of Wall Street — just not in the “dream scenario” bucket anymore.